CRISPR Therapeutics AG (NASDAQ:CRSP) price on Thursday, May 01, fall -2.43% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $37.73.
A look at the stock’s price movement, the close in the last trading session was $38.67, moving within a range at $37.28 and $38.67. The beta value (5-Year monthly) was 1.844. Turning to its 52-week performance, $67.88 and $30.04 were the 52-week high and 52-week low respectively. Overall, CRSP moved 13.85% over the past month.
CRISPR Therapeutics AG’s market cap currently stands at around $3.26 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-10.
The average forecast suggests up to a 1,083.48% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 56.02M, representing a 50.13% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CRSP is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 6 recommend CRSP as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CRSP’s current price about 2.62% and -5.47% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 48.63, while 7-day volatility ratio is 4.51% and 6.77% in the 30-day chart. Further, CRISPR Therapeutics AG (CRSP) has a beta value of 1.87, and an average true range (ATR) of 2.17. Analysts have given the company’s stock an average 52-week price target of $67, forecast between a low of $65 and high of $95. Looking at the price targets, the low is -72.28% off current price level while to achieve the yearly target high, price needs to move -151.79%. Nonetheless, investors will most likely welcome a -77.58% jump to $67 which is the analysts’ median price.
If we refocus on CRISPR Therapeutics AG (NASDAQ:CRSP), historical trading data shows that trading volumes averaged 1.61 over the past 10 days and 2.23 million over the past 3 months. The company’s latest data on shares outstanding shows there are 85.74 million shares.
The 4.33% of CRISPR Therapeutics AG’s shares are in the hands of company insiders while institutional holders own 71.82% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 20.76 million on 2025-04-15, giving us a short ratio of 8.87. The data shows that as of 2025-04-15 short interest in CRISPR Therapeutics AG (CRSP) stood at 2733.9999999999995 of shares outstanding, with shares short rising to 20.31 million registered in 2025-03-14. Current price change has pushed the stock -4.14% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CRSP stock continues to rise going into the next quarter.
